Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.


Creative Commons License

Karadag O., Farisogullari B., Yagiz B., Erden A., Ademoglu Z., Kimyon G., ...Daha Fazla

Clinical and experimental rheumatology, cilt.42, ss.130-137, 2024 (SCI-Expanded) identifier identifier